31 May 2023 -  Sanofi announced on Tuesday that Dupixent, the world's first targeted biological agent for atopic dermatitis treatment, has been approved by China's National Medical Products Administration to treat moderate to severe atopic dermatitis in infants and children aged between six months old and five years old.

It means that the innovative injection has become so far the first and only targeted biological agent approved for the treatment of moderate to severe atopic dermatitis covering all age groups from infancy to adulthood. It is also the first therapeutic biological agent of its kind to be used in infants and young children aged six months and above.

Read China Daily article